Ruijian Pharmaceuticals Secures RMB 210 Million in Series C1 Financing to Advance AI-Driven Universal Cell Therapy Platform

A Globally Leading Universal Cell Therapy Platform CompanyiRegene Announces Completion of RMB 210 Million Series C1 Financing RoundiRegene recently announced the completion of its RMB 210 million Series C1 financing round, jointly led by Guanghe Venture Capital and Apricot Capital. The proceeds will be primarily used to advance the company’s core clinical pipeline, continuously upgrade its AI-driven chemically induced pluripotent stem cell platform, build a large-scale production system, and expand global clinical development and international commercial partnerships.

Dr. Wei Jun, Co-founder and CEO of iRegene, stated, “The completion of this round of financing marks a significant milestone in iRegene’s development. We will continue to center our efforts on the AI + chemical induction platform, continuously expanding our portfolio of platform-based products. In addressing major diseases that remain inadequately treated worldwide, we aim to propel China’s original cell therapies onto the international stage through more efficient execution, a broader global perspective, and more pioneering clinical development strategies.”

iRegene’s pipeline strategy is precisely centered around this large, long-term market. Starting with neurodegenerative diseases, the company has established a clear path for platform expansion. This means that iRegene’s commercial potential is not limited to a single indication, but rather targets a global disease market driven by population aging, characterized by strong certainty of long-term growth and substantial unmet clinical needs.

By leveraging its proprietary AI-driven chemical induction platform, iRegene employs small-molecule compounds to precisely regulate key cellular nodes, thereby enabling the efficient, stable, and scalable production of target functional cells. In addition to NouvNeu001, iRegene has developed a diverse pipeline of innovative candidates based on the same AI-driven chemical induction platform, gradually establishing a product portfolio that covers central nervous system disorders, ophthalmic diseases, and other major therapeutic areas.